title: Dienogest, a new conservative strategy for extragenital endometriosis: a pilot study.
abstract: Extragenital endometriosis severely impairs the quality of life for affected women but its standard management has not yet been well established because of its relatively low incidence. As extragenital organs, intestine, followed by urinary tract, is the most common place affected by endometriosis, for which surgical treatment is sometimes difficult and accompanied by severe complications. Recently, dienogest, a novel progestin, has emerged as a new alternative for endometriosis, especially for endometriosis-associated pain. In this report, we presented four cases with rectosigmoidal and one with bladder endometriosis, treated with oral 2 mg/day dienogest for over 6 months. For all cases, the measurable extragenital lesions exhibited the reduction in their size after 10 to 11 months of use, accompanied with immediate relief of subjective symptoms related with extragenital lesions. This report suggests that dienogest can be a novel conservative alternative for extragenital endometriosis.
authors.affiliation: Faculty of Medicine, Department of Obstetrics and Gynecology, The University of Tokyo, Tokyo, Japan.
authors.forename: Miyuki
authors.initials: M
authors.lastname: Harada
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Osuga
authors.forename: Gentaro
authors.initials: G
authors.lastname: Izumi
authors.forename: Masashi
authors.initials: M
authors.lastname: Takamura
authors.forename: Yuri
authors.initials: Y
authors.lastname: Takemura
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Hirata
authors.forename: Osamu
authors.initials: O
authors.lastname: Yoshino
authors.forename: Kaori
authors.initials: K
authors.lastname: Koga
authors.forename: Tetsu
authors.initials: T
authors.lastname: Yano
authors.forename: Yuji
authors.initials: Y
authors.lastname: Taketani
mesh_terms: D000328:Adult; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D004715:Endometriosis / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008875:Middle Aged; D009277:Nandrolone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010865:Pilot Projects; D012002:Rectal Diseases / Q000188:drug therapy; D012189:Retrospective Studies; D012810:Sigmoid Diseases / Q000188:drug therapy; D001745:Urinary Bladder Diseases / Q000188:drug therapy
chemical_list: D018931:Antineoplastic Agents, Hormonal; C023635:dienogest; D009277:Nandrolone